DUBLIN--(BUSINESS WIRE)--The "MAP Kinase Kinase 1 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This "MAP kinase kinase 1 inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in MAP kinase kinase 1 inhibitors pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

MAP kinase kinase 1 inhibitors: Overview

MAPK kinases 1 and 2 (commonly known as MEK1-2) represent such proteins as they lie downstream of important drug targets for oncology, such as EGFR, RAS and RAF. MEK inhibitors hold promise for use as combination therapies for highly prevalent, genetically defined cancers owing to the critical role that the MAPK pathway plays in the growth and proliferation of many cancer types (including lung cancer, melanoma, pancreatic cancer, colorectal cancer, endometrial cancer, and ovarian cancer).

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence MAP kinase kinase 1 inhibitors R&D. The therapies under development are focused on novel approaches for MAP kinase kinase 1 inhibitors.

MAP kinase kinase 1 inhibitors Emerging Drugs Chapters

This segment of the MAP kinase kinase 1 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

MAP kinase kinase 1 inhibitors Emerging Drugs

Selumetinib: AstraZeneca

Selumetinib is a MEK 1/2 inhibitor used in pediatric patients to treat neurofibromatosis type 1 (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN). Selumetinib is a non-ATP-competitive mitogen-activated protein kinase kinase 1 and 2 (MEK1 and MEK2) inhibitor 6.

By selectively targeting MEK1 and MEK2, selumetinib is able to inhibit oncogenic downstream effects of the Raf-MEK-ERK signaling pathway, which is often overactive in certain types of cancer.

Mirdametinib: SpringWorks Therapeutics

Mirdametinib is an oral, allosteric, small molecule MEK inhibitor in development as a monotherapy treatment for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) and low-grade glioma (LGG), and as a combination therapy for the treatment of several subsets of biomarker-defined metastatic solid tumors. A Phase 2 investigator-initiated trial of mirdametinib in adolescents and adults with NF1-PN showed encouraging efficacy along with a generally well-tolerated safety profile.

The U.S. Food and Drug Administration (FDA) and the European Commission granted Orphan Drug designation for mirdametinib for the treatment of NF1, and the FDA granted Fast Track designation for the treatment of patients ? 2 years of age with NF1-PN that are progressing or causing significant morbidity.

Phases

This report covers around 6+ products under different phases of clinical development like

• Late-stage products
• Mid-stage products
• Early-stage products
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

MAP kinase kinase 1 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Key Players

• AstraZeneca
• SpringWorks Therapeutics
• Array BioPharma
• Novartis
• Chongqing Fochon Pharmaceutical
• Recursion Pharmaceuticals
• CStone Pharmaceuticals

Key Products

• Selumetinib
• Mirdametinib
• Binimetinib
• Trametinib
• FCN 159
• REC 4881
• CS 3006

Key Topics Covered:

Introduction

Executive Summary

MAP kinase kinase 1 inhibitors: Overview

• Structure
• Mechanism of Action

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

MAP kinase kinase 1 inhibitors - Analytical Perspective

Late Stage Products (Phase III)

• Comparative Analysis

Selumetinib: AstraZeneca

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

Mirdametinib: SpringWorks Therapeutics

• Product Description
• Research and Development
• Product Development Activities

Early Stage Products (Phase I and I/II)

• Comparative Analysis

CS 3006: CStone Pharmaceuticals

• Product Description
• Research and Development
• Product Development Activities

Pre-clinical and Discovery Stage Products

• Comparative Analysis

REC 4881: Recursion Pharmaceuticals

• Product Description
• Research and Development
• Product Development Activities

Inactive Products

• Comparative Analysis

MAP kinase kinase 1 inhibitors Key Companies

MAP kinase kinase 1 inhibitors Key Products

MAP kinase kinase 1 inhibitors- Unmet Needs

MAP kinase kinase 1 inhibitors- Market Drivers and Barriers

MAP kinase kinase 1 inhibitors- Future Perspectives and Conclusion

MAP kinase kinase 1 inhibitors Analyst Views

MAP kinase kinase 1 inhibitors Key Companies

Appendix

For more information about this drug pipelines report visit

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900